Abstract: Diabetes is describe as a disease of the thirst (undaasah) in the four foundations of traditional drug (Kh. Tumbaa, 1991).
There are drugs such as Jur Ur-4, Sopagi-14, Yunva-4 and Usu-3 used for thirst disease. One of the main medicines used in Mongolian traditional drug is “Usu-3”. This is drug with 3 ingredients (Coriandrum sativum L.), (Inula helenium L.), (Hippophae rhamnoides L.). Each of these ingredients were studied indivudually, but not studied in combination. Purpose: To study liver protection effects and toxicity of the “Usu-3” traditional drug in the pathological diabetic model. Methods: The experiment were performed using acute and chronic toxicity study by Organization economic cooperation development (OECD 423), effect of antihyperglycemic and antihyperlipidemic on the alloxan induced diabetic milletus. (Sheriff Modu*, A. Laila et al, 2011) and (Ju JB, Kim JS et al, 2008) method. Results:
1. The “Usu-3” traditional drug was tested in animals at a dose of 5 to 5000 mg/kg in accordance with OECD guideline 423 for acute toxicity study and was found to be harmless in the GHS category. Therefore showed no signs of chronic poisoning with the maximum dose determined for chronic toxicity studies oral administration by 5000mg/kg for 2 months.
2. The “Usu-3” traditional drug’s group has been shown to reducing the levels of Aspartate Aminotransferase and Alanine Aminotransferease comparison with other groups. Conclusion “Usu-3” traditional drug was found to be harmless in the GHS category, showed no signs of acute and chronic toxicity.
“Usu-3” traditional drug have a protection effect for liver at short and medium time in alloxan induced diabetic rats model.

Abstract: Noncommunicable diseases (NCDs) kill 41 million people each year, equivalent to 71% of all deaths globally and diabetes is one of the top 5 causes of these diseases.According to Mongolia's health statistics, diabetes accounted for 41.5% of all diseases of endocrine, nutritional and metabolic disorders and the morbidity rate was 82.9 per 10 000 population in 2018.
We chose to study the Usu-3 traditional medicine, which has been used in medicine for diabetes. Purpose: The study of effects for "Usu-3" traditional medicine in alloxan-induced diabetic model Methods: The experiment were performed using (Sheriff Modu*, A. Laila et al, 2011) and (Ju JB, Kim JSet al, 2008) method. Results: The "Usu-3" traditional drug has been shown to have a gradual effect on lowering serum glucose in short time and normal level in medium time. Therefore as well as normal levels of lipids in all groups. Conclusion "Usu-3" traditional drug has been shown to gradually lower blood serum glucose and when to study the antihyperglycaemic and antihyperlipidaemic effects of "Usu-3" traditional drug at in alloxan induced diabetic rats.

BACKGROUND. Sensorineural hearing impairment (SNHI) is the most common inherited sensory defect, affecting about 3 per 1000 children. More than 50% of these patients have a genetic cause (i.e. hereditary hearing impairment; HHI). Mutations in certain genes were noted to be extraordinarily popular in the deaf patients across different populations, making molecular screening feasible for these common deafness genes. One of the most important characteristics that we have learned concerning hereditary hearing loss is that common deafness genes and their mutations are usually different according to the ethnic background. As demonstrated in our previous studies performed in Taiwanese patients, the mutation spectrums of common deafness genes, such as the GJB2 gene and the SLC26A4 gene, are different from those in the Caucasian or even other Asian populations. These findings further underscore the indispensability of the collection of local data in terms of genetic counseling. In the collaborative project, we have successfully established a cohort of >100 hearing-impaired families, and clarified the genetic epidemiology of deafness in the Mongolian population. We identified several special deafness mutations such as GJB2 c.23+1G>A, c.559_604dup, and SLC26A4 c.919-2A>G, and our results revealed that Mongolian patients demonstrate a unique genetic profile in deafness as compared to other East Asian populations (paper in preparation). Meanwhile, by organizing a seminar at National Taiwan University Hospital in March 2017, we have transferred crucial concepts and techniques regarding how to perform genetic testing for deafness to the Mongolian colleagues. In the future, we plan to strengthen the mutual collaboration by expanding the clinical cohort and upgrading the genetic examination platform using the NGS techniques.

BACKGROUND. Sensorineural hearing impairment (SNHI) is the most common inherited sensory defect, affecting about 3 per 1000 children. More than 50% of these patients have a genetic cause (i.e. hereditary hearing impairment; HHI). Mutations in certain genes were noted to be extraordinarily popular in the deaf patients across different populations, making molecular screening feasible for these common deafness genes. One of the most important characteristics that we have learned concerning hereditary hearing loss is that common deafness genes and their mutations are usually different according to the ethnic background. As demonstrated in our previous studies performed in Taiwanese patients, the mutation spectrums of common deafness genes, such as the GJB2 gene and the SLC26A4 gene, are different from those in the Caucasian or even other Asian populations. These findings further underscore the indispensability of the collection of local data in terms of genetic counseling. In the collaborative project, we have successfully established a cohort of >100 hearingimpaired families, and clarified the genetic epidemiology of deafness in the Mongolian population. We identified several special deafness mutations such as GJB2 c.23+1G>A, c.559_604dup, and SLC26A4 c.919-2A>G, and our results revealed that Mongolian patients demonstrate a unique genetic profile in deafness as compared to other East Asian populations (paper in preparation). Meanwhile, by organizing a seminar at National Taiwan University Hospital in March 2017, we have transferred crucial concepts and techniques regarding how to perform genetic testing for deafness to the Mongolian colleagues. In the future, we plan to strengthen the mutual collaboration by expanding the clinical cohort and upgrading the genetic examination platform using the NGS techniques.